Literature DB >> 11084691

Targeted single-base correction by RNA-DNA oligonucleotides.

O Igoucheva1, K Yoon.   

Abstract

An oligonucleotide composed of a contiguous stretch of RNA and DNA residues has been developed to facilitate correction of single-base mutations of episomal and chromosomal targets in mammalian cells. We demonstrated that an RNA-DNA oligonucleotide (RDO) induced heritable correction of a point mutation in the tyrosinase gene at the level of genomic sequence, protein, and phenotype of albino mouse melanocytes and albino mouse skin. Such RDOs might hold promise as a therapeutic method for the treatment of skin diseases. However, the general application of RDO technology has been hampered by the absence of a standardized system to measure the gene conversion in a particular cell type in a rapid and reproducible manner. For this purpose, we established an in vitro system in which nuclear extracts from mammalian cells showed RDO-mediated gene correction of a shuttle vector containing a point mutation in the E. coli beta-galactosidase gene. This sensitive and convenient assay has been utilized to optimize the design of RDOs and to compare frequencies of gene conversion among different cell types. The general application of the RDO for site-specific gene correction or mutation would benefit from such mechanistic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084691     DOI: 10.1089/104303400750035861

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  2 in total

1.  Transcription affects formation and processing of intermediates in oligonucleotide-mediated gene alteration.

Authors:  Olga Igoucheva; Vitali Alexeev; Melissa Pryce; Kyonggeun Yoon
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

2.  Chimeric RNA/DNA oligonucleotide-based site-specific modification of the tobacco acetolactate syntase gene.

Authors:  Andrej Kochevenko; Lothar Willmitzer
Journal:  Plant Physiol       Date:  2003-05       Impact factor: 8.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.